MedTech Venture Partners
MedTech Venture Partners is a venture capital firm that provides funding and support to medical technology entrepreneurs. With a team that has extensive experience in overseeing the development and launch of over 30 medical devices and diagnostics products, the company focuses on scaling early stage device businesses and leveraging clinical and regulatory expertise globally. Additionally, they have been involved in buying and selling technologies, products, and companies, enhancing their ability to understand and assist device entrepreneurs in achieving success. Working in collaboration with partners at UCSF, MedTech Venture Partners is dedicated to building a thriving ecosystem around early stage medical devices.
Top Regions
Top Stages
10 past transactions
GT Medical Technologies
Series D in 2025
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
Zenflow
Series C in 2024
Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.
Centese
Series B in 2023
Centese is a medical device company that develops Thoraguard, a digital postoperative drainage system for cardiothoracic surgery. The system uses integrated sensors, algorithms, and a battery-powered controller to monitor chest tube drainage and other fluids, providing real-time data to support clinical decisions and automatic chest tube clearing for safety. The technology aims to reduce complications, support quicker recovery after open-heart or open-lung procedures, and improve post-operative patient outcomes by offering reliable monitoring and actionable insights for clinicians.
GT Medical Technologies
Series C in 2023
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
Akura Medical
Series A in 2022
Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.
GT Medical Technologies
Series B in 2020
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
GT Medical Technologies
Series A in 2019
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
PQ Bypass
Venture Round in 2019
PQ Bypass is a medical device company based in Milpitas, California, focused on transforming the treatment of long-segment peripheral artery disease through minimally-invasive endovascular solutions. Founded in 2009, the company develops and manufactures devices such as the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System to treat peripheral vascular disease via percutaneous surgical bypass. The executive team at PQ Bypass includes recognized leaders from the medical device industry with extensive experience in developing innovative solutions for venture-backed startups and major corporations like Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker.
Zenflow
Series A in 2018
Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.
GT Medical Technologies
Seed Round in 2018
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.